IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:
- Guggenheim 3rd Annual Healthcare Conference on Tuesday, November 10th, where management plans to participate in a fireside chat at 12:30 p.m. PT / 3:30 p.m. ET.
- 2026 Jefferies Global Healthcare Conference on Wednesday, November 18th and Thursday, November 19th.
- Piper Sandler 38th Annual Healthcare Conference on Tuesday, December 1st, where management plans to participate in a fireside chat at 11:30 a.m. PT / 2:30 p.m. ET.
Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of ocular rosacea, TP-05 as an oral tablet for the potential prevention of Lyme disease, IRX-101 for potential use as an ocular antiseptic and gildeuretinol for the potential treatment of Stargardt disease.
Media Contact:
Adrienne Kemp
Vice President, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com
